Aligning Mutual Interests to Build Long-Term Partnerships: Interview with Alio CEO Dave Kuraguntla

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded04 Jun 2023

Publisherfeeds.transistor.fm ↗

Handlerec:13866304

Show notes

In this episode of Medsider Radio, we sat down with Dave Kuraguntla, co-founder and CEO of Alio, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.